What are the main drugs for bladder cancer

What are the main drugs for bladder cancer? Bladder cancer is a common malignant tumor. There are many drugs that can be used in the clinical treatment of bladder cancer. Bladder cancer patients should use drugs with caution under the guidance of doctors. At the same time, when purchasing drugs, bladder cancer patients need to consider drug ingredients, drug efficacy and adverse reactions. At the same time, they also need to pay attention to drug contraindications. Pregnant women, infants and other special groups need to be more cautious in choosing drugs. Here, we recommend several commonly used drugs for bladder cancer for patients, hoping to help bladder cancer patients with medication.

What are the best medicines for bladder cancer?

1. Keto (doxifluridine capsules)

Ingredients: Doxifluridine.

Functions and indications: This product is used to treat gastric cancer, colon cancer, rectal cancer, breast cancer, cervical cancer, and bladder cancer.

Dosage and Administration: Oral administration, total amount per day 0.8-1.2g (4-6 tablets), divided into 3-4 times, and the dosage can be increased or decreased appropriately according to age and symptoms, or as directed by a doctor. When used with other anti-tumor drugs, please follow the doctor's advice.

Contraindications: 1. Patients with a history of allergy to this product. 2. Pregnant and lactating women. 3. Patients currently receiving sorivudine treatment.

2. Hydroxycamptothecin for injection

Ingredients: The main ingredient of this product is hydroxycamptothecin. The auxiliary materials are glycine, mannitol and sodium hydroxide.

Functions and indications: This product is an anti-tumor drug, suitable for primary liver cancer, gastric cancer, bladder cancer, rectal cancer, head epithelial cancer, leukemia and other malignant tumors.

Contraindications: Do not use if you are allergic to this product.

3. Recombinant human interleukin-2 (125Ala) for injection

Ingredients: The main ingredient of this product is recombinant human interleukin-2 ([sup]125[/sup]Ala), which is derived from genetically engineered recombinant Escherichia coli. The auxiliary materials are mannitol, sodium dodecyl sulfate, disodium hydrogen phosphate, sodium dihydrogen phosphate, and human serum albumin.

Functions and indications: 1. It is used to treat malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, rectal cancer, lymphoma, lung cancer, etc. It is used to control cancerous pleural effusion and ascites, and can also be used to cultivate lymphokine-activated killer cells. 2. It is used to treat tumor patients after surgery, radiotherapy and chemotherapy, and can enhance the body's immune function. 3. It is used to treat congenital or acquired immunodeficiency, and improve the patient's cellular immune function and anti-infection ability. 4. It is used to treat various autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, etc. 5. It has a certain therapeutic effect on certain viral, bacillary diseases, and intracellular parasitic infectious diseases, such as hepatitis B, leprosy, tuberculosis, and Candida albicans infection.

Dosage and administration: Dissolve in sterile water for injection. The specific usage, dosage and course of treatment vary according to the disease. Generally, the following methods are used (or follow the doctor's advice). 1. Systemic administration: (1) Subcutaneous injection: recombinant human interleukin-2 ([sup]125[/sup]Ala) 601.5 million IU/m[sup]2[/sup] (1~2 vials) dissolved in 2ml water for injection, subcutaneously injected 3 times/week, 6 weeks as a course of treatment. (2) Intravenous injection: 40.8 million IU/m[sup]2[/sup] (1~2 vials), dissolved in 500ml normal saline, drip for no less than 4 hours, three times a week, 6 weeks as a course of treatment. (3) Interventional arterial perfusion: 500,000~1 million IU/time (1~2 vials), once every 2~4 weeks, 2~4 times as a course of treatment. 2. Regional and local administration: (1) Pleural injection: For cancerous pleural effusion, recombinant human interleukin-2 ([sup]125[/sup]Ala) 1 to 2 million IU/m[sup]2[/sup] times (1 to 2 vials), try to remove the effusion in the cavity and then inject, 1 to 2 times/week, 2 to 4 weeks (or the effusion disappears) as a course of treatment. (2) Local administration of tumor lesions: The dosage is determined according to the size of the tumor, each dose is not less than 100,000 IU, once every other day, 4 to 6 times as a course of treatment.

Contraindications: The following patients are prohibited from using this product: 1. Patients with a history of allergy to the ingredients of this product. 2. Patients with high fever, severe heart disease, hypotension, severe heart and kidney failure, abnormal lung function or those who have undergone organ transplantation. 3. Recombinant human interleukin-2, or patients with a history of toxic reactions related to it: (1) Sustained ventricular tachycardia. (2) Uncontrolled arrhythmia. (3) Chest pain accompanied by electrocardiographic changes, angina pectoris or myocardial infarction. (4) Cardiac tamponade. (5) Renal failure requiring dialysis for >72 hours. (6) Coma or toxic psychosis for >48 hours. (7) Intractable or intractable epilepsy. (8) Local intestinal ischemia or perforation. (9) Gastrointestinal bleeding requiring surgery.